Over the last decade, the Centers for Medicare and Medicaid Services (CMS) launched several initiatives tied to incentives to “providers” to improve care. A peer-reviewed study spins out to interested clinicians the clinical benefits and financial costs of an initiative to reduce cardiovascular disease. The full report to CMS spells out the failures.
cardiovascular disease prevention
The Lancet reports on a polypill containing aspirin, blood pressure medicine and a statin. For a large at-risk population, it reduced major cardiovascular events by 20 to 33% ... and for about $1.25 a month.
The United States Preventive Services Task Force has issued its final recommendations for aspirin use, as it applies to the prevention of cardiovascular disease and colorectal cancer. It mostly pertains to those in the 50-to-59 and 60-to-69 age groups.